These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Letter by Tromp et al Regarding Article, "Large-Scale Screening for Monogenic and Clinically Defined Familial Hypercholesterolemia in Iceland". Tromp TR; Hovingh GK; Reeskamp LF Arterioscler Thromb Vasc Biol; 2022 Jan; 42(1):e44-e45. PubMed ID: 34936472 [No Abstract] [Full Text] [Related]
8. Recognition and Treatment of Homozygous Familial Hypercholesterolemia by Primary Care Physicians: a Survey from the National Lipid Association. Hemphill L; Goldberg A; Hovingh K; Cohen J; Karalis DG J Gen Intern Med; 2020 Jul; 35(7):2225-2227. PubMed ID: 31950403 [No Abstract] [Full Text] [Related]
9. Response by Björnsson et al to Letter Regarding Article, "Large-Scale Screening for Monogenic and Clinically Defined Familial Hypercholesterolemia in Iceland". Björnsson E; Thorgeirsson G; Helgadóttir A; Gudbjartsson DF; Hólm H; Thorsteinsdóttir U; Sulem P; Stefánsson K Arterioscler Thromb Vasc Biol; 2022 Jan; 42(1):e46-e47. PubMed ID: 34936471 [No Abstract] [Full Text] [Related]
10. Results and Lessons of a Pilot Study of Cascade Screening for Familial Hypercholesterolemia in US Primary Care Practices. Neuner J; Dimmock D; Kirschner AP; Beaudry H; Paradowski J; Orlando L J Gen Intern Med; 2020 Jan; 35(1):351-353. PubMed ID: 31667742 [No Abstract] [Full Text] [Related]
12. Screening for familial hypercholesterolemia: what is the most effective strategy? Daniels SR Nat Clin Pract Cardiovasc Med; 2008 Mar; 5(3):130-1. PubMed ID: 18059381 [No Abstract] [Full Text] [Related]
13. Management of familial heterozygous hypercholesterolemia. Position paper of the Polish Lipid Expert Forum. Rynkiewicz A; Cybulska B; Banach M; Filipiak KJ; Guzik T; Idzior-Waluś B; Imiela J; Jankowski P; Kłosiewicz-Latoszek L; Limon J; Myśliwiec M; Opolski G; Steciwko A; Stępińska J; Zdrojewski T Pol Arch Med Wewn; 2013; 123(1-2):7-10. PubMed ID: 23449188 [No Abstract] [Full Text] [Related]
15. [Familial hypercholesterolemia: A largely underestimated cardiovascular risk]. Ferrières J; Bruckert É; Béliard S; Rabès JP; Farnier M; Krempf M; Cariou B; Danchin N Ann Cardiol Angeiol (Paris); 2018 Feb; 67(1):1-8. PubMed ID: 28576280 [TBL] [Abstract][Full Text] [Related]
16. Single Nucleotide Variants Associated With Polygenic Hypercholesterolemia in Families Diagnosed Clinically With Familial Hypercholesterolemia. Lamiquiz-Moneo I; Pérez-Ruiz MR; Jarauta E; Tejedor MT; Bea AM; Mateo-Gallego R; Pérez-Calahorra S; Baila-Rueda L; Marco-Benedí V; de Castro-Orós I; Cenarro A; Civeira F Rev Esp Cardiol (Engl Ed); 2018 May; 71(5):351-356. PubMed ID: 28919240 [TBL] [Abstract][Full Text] [Related]
17. [Management of familial heterozygous hypercholesterolaemia. Position paper of the Polish Lipid Expert Forum]. Rynkiewicz A; Cybulska B; Banach M; Filipiak KJ; Guzik T; Idzior Waluś B; Imiela J; Jankowski P; Kłosiewicz Latoszek L; Limon J; Myśliwiec M; Opolski G; Steciwko A; Stępińska J; Zdrojewski T; Kardiol Pol; 2013; 71(1):107-11. PubMed ID: 23348551 [No Abstract] [Full Text] [Related]
18. The treatment of heterozygous familial hypercholesterolemia - a local perspective. Bułdak Ł Endokrynol Pol; 2021; 72(3):189-190. PubMed ID: 34292576 [TBL] [Abstract][Full Text] [Related]
19. What Is Familial Hypercholesterolemia, and Why Does It Matter? Khera AV; Hegele RA Circulation; 2020 Jun; 141(22):1760-1763. PubMed ID: 32479201 [No Abstract] [Full Text] [Related]
20. Familial hypercholesterolemia: experience from the French-Canadian population. Paquette M; Genest J; Baass A Curr Opin Lipidol; 2018 Apr; 29(2):59-64. PubMed ID: 29356704 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]